NASDAQ:IOVA - Nasdaq - US4622601007 - Common Stock - Currency: USD
NASDAQ:IOVA (5/22/2025, 10:39:39 AM)
1.74
-0.02 (-1.14%)
The current stock price of IOVA is 1.74 USD. In the past month the price decreased by -44.98%. In the past year, price decreased by -82.47%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.62 | 320.03B | ||
AMGN | AMGEN INC | 13.02 | 145.30B | ||
GILD | GILEAD SCIENCES INC | 13.82 | 133.18B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.20B | ||
REGN | REGENERON PHARMACEUTICALS | 13.5 | 64.59B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.23B | ||
ARGX | ARGENX SE - ADR | 99.25 | 35.57B | ||
ONC | BEIGENE LTD-ADR | 5.94 | 25.76B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.59B | ||
NTRA | NATERA INC | N/A | 20.76B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.69B | ||
BIIB | BIOGEN INC | 7.95 | 18.43B |
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 838 full-time employees. The company went IPO on 2008-06-20. The firm develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The firm also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The firm is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
IOVANCE BIOTHERAPEUTICS INC
825 Industrial Road, 4th Floor
San Carlos CALIFORNIA 94070 US
CEO: Maria Fardis
Employees: 838
Phone: 16502607120
The current stock price of IOVA is 1.74 USD. The price decreased by -1.14% in the last trading session.
The exchange symbol of IOVANCE BIOTHERAPEUTICS INC is IOVA and it is listed on the Nasdaq exchange.
IOVA stock is listed on the Nasdaq exchange.
19 analysts have analysed IOVA and the average price target is 19.57 USD. This implies a price increase of 1024.45% is expected in the next year compared to the current price of 1.74. Check the IOVANCE BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
IOVANCE BIOTHERAPEUTICS INC (IOVA) has a market capitalization of 581.04M USD. This makes IOVA a Small Cap stock.
IOVANCE BIOTHERAPEUTICS INC (IOVA) currently has 838 employees.
IOVANCE BIOTHERAPEUTICS INC (IOVA) has a resistance level at 1.92. Check the full technical report for a detailed analysis of IOVA support and resistance levels.
The Revenue of IOVANCE BIOTHERAPEUTICS INC (IOVA) is expected to grow by 81.52% in the next year. Check the estimates tab for more information on the IOVA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IOVA does not pay a dividend.
IOVANCE BIOTHERAPEUTICS INC (IOVA) will report earnings on 2025-08-06, after the market close.
IOVANCE BIOTHERAPEUTICS INC (IOVA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.24).
The outstanding short interest for IOVANCE BIOTHERAPEUTICS INC (IOVA) is 26.08% of its float. Check the ownership tab for more information on the IOVA short interest.
ChartMill assigns a fundamental rating of 3 / 10 to IOVA. IOVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months IOVA reported a non-GAAP Earnings per Share(EPS) of -1.24. The EPS increased by 31.11% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -40.88% | ||
ROE | -52.39% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to IOVA. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 18.69% and a revenue growth 81.52% for IOVA